These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9717972)

  • 1. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis.
    Johnson N; Parkin JM
    Clin Exp Immunol; 1998 Aug; 113(2):229-34. PubMed ID: 9717972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in HIV-1 viral loads between male and female antiretroviral-untreated Mexican patients.
    Ballesteros-Zebadúa P; Villarreal C; Cocho G; Huerta L; Estrada JL
    Arch Med Res; 2013 May; 44(4):296-301. PubMed ID: 23608673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS. Molecular control and effect of highly active anti-retroviral therapy.
    Gougeon ML; Montagnier L
    Ann N Y Acad Sci; 1999; 887():199-212. PubMed ID: 10668476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis.
    Moretti S; Alesse E; Marcellini S; Di Marzio L; Zazzeroni F; Parroni R; Famularo G; Boschini A; Cifone MG; De Simone C
    Immunopharmacol Immunotoxicol; 1999 Nov; 21(4):645-65. PubMed ID: 10584202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early increase of CD4+ CD45RA+ and CD4+ CD95- cells with conserved repertoire induced by anti-retroviral therapy in HIV-infected patients.
    Silvestri G; Munoz-Calleja C; Bagnarelli P; Piedimonte G; Clementi M; Montroni M
    Clin Exp Immunol; 1998 Jan; 111(1):3-11. PubMed ID: 9472655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of N-acetyl-L-cysteine on lymphocyte apoptosis, lymphocyte viability, TNF-alpha and IL-8 in HIV-infected patients undergoing anti-retroviral treatment.
    Treitinger A; Spada C; Masokawa IY; Verdi JC; Van Der Sander Silveira M; Luis MC; Reis M; Ferreira SI; Abdalla DS
    Braz J Infect Dis; 2004 Oct; 8(5):363-71. PubMed ID: 15798812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.
    Sousa AE; Chaves AF; Doroana M; Antunes F; Victorino RM
    Clin Exp Immunol; 1999 May; 116(2):307-15. PubMed ID: 10337023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
    Davey RT; Bhat N; Yoder C; Chun TW; Metcalf JA; Dewar R; Natarajan V; Lempicki RA; Adelsberger JW; Miller KD; Kovacs JA; Polis MA; Walker RE; Falloon J; Masur H; Gee D; Baseler M; Dimitrov DS; Fauci AS; Lane HC
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15109-14. PubMed ID: 10611346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
    AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.
    Okulicz JF; Le TD; Agan BK; Camargo JF; Landrum ML; Wright E; Dolan MJ; Ganesan A; Ferguson TM; Smith DM; Richman DD; Little SJ; Clark RA; He W; Ahuja SK
    JAMA Intern Med; 2015 Jan; 175(1):88-99. PubMed ID: 25419650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial.
    Soria A; Trabattoni D; Squillace N; Rainone V; Gnudi F; Clerici M; Gori A; Bandera A
    PLoS One; 2015; 10(2):e0117118. PubMed ID: 25671649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
    Lim A; Tan D; Price P; Kamarulzaman A; Tan HY; James I; French MA
    AIDS; 2007 Jul; 21(12):1525-34. PubMed ID: 17630546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.